High-Dose-Rate Brachytherapy Treatment Planning Software Receives FDA Clearance
By MedImaging International staff writers Posted on 11 Feb 2013 |
A new application enables clinicians to plan and perform high-dose-rate (HDR) brachytherapy treatments for prostate cancer using real-time ultrasound guidance.
Varian Medical Systems (Palo Alto, CA, USA) has received a US Food and Drug Administration (FDA) 510(k) clearance for the latest version of its Vitesse real-time planning for HDR brachytherapy, which is used to plan and perform high-dose-rate (HDR), ultrasound-guided brachytherapy treatments for prostate cancer.
“This version of Vitesse reduces the number and complexity of steps involved in planning and completing a treatment. It eliminates the need for a data transfer to another software program, and avoids moving the patient to a CT [computed tomography] scanner for images in the middle of the procedure. For these reasons, most clinicians will see a reduction in the amount of time needed to complete these treatments, often by as much as an hour and a half,” said Tim Clark, marketing manager for Varian brachytherapy.
HDR brachytherapy involves delivering radiotherapy from inside the body by temporarily placing a tiny radioactive source directly into the tumor or other targeted area. Using a robotic device called an afterloader, clinicians place the radioactive source into positions through needles that have been inserted into the area being treated. The source is then moved within the needles under computer control to create the specified dose distribution within the patient’s anatomy.
Using the latest version of Vitesse, HDR brachytherapy treatment plans can be created in a real-time environment, using ultrasound images generated in the operating room rather than CT scans generated elsewhere. This avoids the need to move the patient to a CT scanner room for imaging after the needles have been put in place. The process can now be completed entirely within the Vitesse program, from capturing the ultrasound image to finalizing an approved treatment plan.
In addition to receiving FDA 510(k) clearance, which permits sale of the Vitesse software in the United States, Varian has also obtained the CE Marking, which permits sales in the European Union and other countries where the marking is recognized.
Related Links:
Varian Medical Systems
Varian Medical Systems (Palo Alto, CA, USA) has received a US Food and Drug Administration (FDA) 510(k) clearance for the latest version of its Vitesse real-time planning for HDR brachytherapy, which is used to plan and perform high-dose-rate (HDR), ultrasound-guided brachytherapy treatments for prostate cancer.
“This version of Vitesse reduces the number and complexity of steps involved in planning and completing a treatment. It eliminates the need for a data transfer to another software program, and avoids moving the patient to a CT [computed tomography] scanner for images in the middle of the procedure. For these reasons, most clinicians will see a reduction in the amount of time needed to complete these treatments, often by as much as an hour and a half,” said Tim Clark, marketing manager for Varian brachytherapy.
HDR brachytherapy involves delivering radiotherapy from inside the body by temporarily placing a tiny radioactive source directly into the tumor or other targeted area. Using a robotic device called an afterloader, clinicians place the radioactive source into positions through needles that have been inserted into the area being treated. The source is then moved within the needles under computer control to create the specified dose distribution within the patient’s anatomy.
Using the latest version of Vitesse, HDR brachytherapy treatment plans can be created in a real-time environment, using ultrasound images generated in the operating room rather than CT scans generated elsewhere. This avoids the need to move the patient to a CT scanner room for imaging after the needles have been put in place. The process can now be completed entirely within the Vitesse program, from capturing the ultrasound image to finalizing an approved treatment plan.
In addition to receiving FDA 510(k) clearance, which permits sale of the Vitesse software in the United States, Varian has also obtained the CE Marking, which permits sales in the European Union and other countries where the marking is recognized.
Related Links:
Varian Medical Systems
Latest Imaging IT News
- New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
- Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology
- AI-Based Mammography Triage Software Helps Dramatically Improve Interpretation Process
- Artificial Intelligence (AI) Program Accurately Predicts Lung Cancer Risk from CT Images
- Image Management Platform Streamlines Treatment Plans
- AI-Based Technology for Ultrasound Image Analysis Receives FDA Approval
- AI Technology for Detecting Breast Cancer Receives CE Mark Approval
- Digital Pathology Software Improves Workflow Efficiency
- Patient-Centric Portal Facilitates Direct Imaging Access
- New Workstation Supports Customer-Driven Imaging Workflow
Channels
Radiography
view channel
World's Largest Class Single Crystal Diamond Radiation Detector Opens New Possibilities for Diagnostic Imaging
Diamonds possess ideal physical properties for radiation detection, such as exceptional thermal and chemical stability along with a quick response time. Made of carbon with an atomic number of six, diamonds... Read more
AI-Powered Imaging Technique Shows Promise in Evaluating Patients for PCI
Percutaneous coronary intervention (PCI), also known as coronary angioplasty, is a minimally invasive procedure where small metal tubes called stents are inserted into partially blocked coronary arteries... Read moreMRI
view channel
AI Tool Tracks Effectiveness of Multiple Sclerosis Treatments Using Brain MRI Scans
Multiple sclerosis (MS) is a condition in which the immune system attacks the brain and spinal cord, leading to impairments in movement, sensation, and cognition. Magnetic Resonance Imaging (MRI) markers... Read more
Ultra-Powerful MRI Scans Enable Life-Changing Surgery in Treatment-Resistant Epileptic Patients
Approximately 360,000 individuals in the UK suffer from focal epilepsy, a condition in which seizures spread from one part of the brain. Around a third of these patients experience persistent seizures... Read more
AI-Powered MRI Technology Improves Parkinson’s Diagnoses
Current research shows that the accuracy of diagnosing Parkinson’s disease typically ranges from 55% to 78% within the first five years of assessment. This is partly due to the similarities shared by Parkinson’s... Read more
Biparametric MRI Combined with AI Enhances Detection of Clinically Significant Prostate Cancer
Artificial intelligence (AI) technologies are transforming the way medical images are analyzed, offering unprecedented capabilities in quantitatively extracting features that go beyond traditional visual... Read moreUltrasound
view channel
AI Identifies Heart Valve Disease from Common Imaging Test
Tricuspid regurgitation is a condition where the heart's tricuspid valve does not close completely during contraction, leading to backward blood flow, which can result in heart failure. A new artificial... Read more
Novel Imaging Method Enables Early Diagnosis and Treatment Monitoring of Type 2 Diabetes
Type 2 diabetes is recognized as an autoimmune inflammatory disease, where chronic inflammation leads to alterations in pancreatic islet microvasculature, a key factor in β-cell dysfunction.... Read moreNuclear Medicine
view channel
Novel PET Imaging Approach Offers Never-Before-Seen View of Neuroinflammation
COX-2, an enzyme that plays a key role in brain inflammation, can be significantly upregulated by inflammatory stimuli and neuroexcitation. Researchers suggest that COX-2 density in the brain could serve... Read more
Novel Radiotracer Identifies Biomarker for Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC), which represents 15-20% of all breast cancer cases, is one of the most aggressive subtypes, with a five-year survival rate of about 40%. Due to its significant heterogeneity... Read moreGeneral/Advanced Imaging
view channel
AI-Powered Imaging System Improves Lung Cancer Diagnosis
Given the need to detect lung cancer at earlier stages, there is an increasing need for a definitive diagnostic pathway for patients with suspicious pulmonary nodules. However, obtaining tissue samples... Read more
AI Model Significantly Enhances Low-Dose CT Capabilities
Lung cancer remains one of the most challenging diseases, making early diagnosis vital for effective treatment. Fortunately, advancements in artificial intelligence (AI) are revolutionizing lung cancer... Read moreIndustry News
view channel
GE HealthCare and NVIDIA Collaboration to Reimagine Diagnostic Imaging
GE HealthCare (Chicago, IL, USA) has entered into a collaboration with NVIDIA (Santa Clara, CA, USA), expanding the existing relationship between the two companies to focus on pioneering innovation in... Read more
Patient-Specific 3D-Printed Phantoms Transform CT Imaging
New research has highlighted how anatomically precise, patient-specific 3D-printed phantoms are proving to be scalable, cost-effective, and efficient tools in the development of new CT scan algorithms... Read more
Siemens and Sectra Collaborate on Enhancing Radiology Workflows
Siemens Healthineers (Forchheim, Germany) and Sectra (Linköping, Sweden) have entered into a collaboration aimed at enhancing radiologists' diagnostic capabilities and, in turn, improving patient care... Read more